{"corpus_id":251478343,"paper_sha":"529b13a6f3c8b3efc9b37991f2e808707bd8ac3e","doi":"10.2147/DDDT.S378450","arxiv_id":null,"pmid":35971530,"pmcid":"9375562","mag_id":null,"dblp_id":null,"acl_id":null,"title":"Brolucizumab for the Treatment of Degenerative Macular Conditions: A Review of Clinical Studies","year":2022,"publication_date":"2022-08-01","venue":"Drug Design, Development and Therapy","journal":{"name":"Drug Design, Development and Therapy","pages":"2659 - 2680","volume":"16"},"journal_issn":null,"journal_title":null,"publication_types":["Review","JournalArticle"],"pubmed_pub_types":["Journal Article","Review"],"s2_fields_of_study":["Medicine"],"reference_count":98,"citation_count":19,"influential_citation_count":0,"is_open_access":true,"arxiv_categories":null,"arxiv_license":null,"arxiv_journal_ref":null,"mesh_headings":[{"d":"Angiogenesis Inhibitors","mj":false,"qs":[{"q":"therapeutic use","mj":false,"ui":"Q000627"}],"ui":"D020533"},{"d":"Antibodies, Monoclonal, Humanized","mj":true,"qs":[{"q":"therapeutic use","mj":false,"ui":"Q000627"}],"ui":"D061067"},{"d":"Diabetic Retinopathy","mj":true,"qs":[{"q":"drug therapy","mj":false,"ui":"Q000188"}],"ui":"D003930"},{"d":"Humans","mj":false,"ui":"D006801"},{"d":"Intravitreal Injections","mj":false,"ui":"D058449"},{"d":"Recombinant Fusion Proteins","mj":false,"qs":[{"q":"therapeutic use","mj":false,"ui":"Q000627"}],"ui":"D011993"},{"d":"Vascular Endothelial Growth Factor A","mj":false,"ui":"D042461"},{"d":"Visual Acuity","mj":false,"ui":"D014792"},{"d":"Wet Macular Degeneration","mj":true,"qs":[{"q":"drug therapy","mj":false,"ui":"Q000188"}],"ui":"D057135"}],"chemicals":[{"n":"Angiogenesis Inhibitors","ui":"D020533","reg":"0"},{"n":"Antibodies, Monoclonal, Humanized","ui":"D061067","reg":"0"},{"n":"Recombinant Fusion Proteins","ui":"D011993","reg":"0"},{"n":"Vascular Endothelial Growth Factor A","ui":"D042461","reg":"0"},{"n":"brolucizumab","ui":"C000622091","reg":"XSZ53G39H5"}],"comments_corrections":null,"source_flags":5,"s2_open_access_pdf_url":"https://www.dovepress.com/getfile.php?fileID=82865","s2_open_access_landing_url":"https://www.semanticscholar.org/paper/529b13a6f3c8b3efc9b37991f2e808707bd8ac3e","s2_open_access_license":"CCBYNC","s2_open_access_status":"GOLD","pmc_open_access_pdf_url":null,"pmc_open_access_landing_url":null,"pmc_open_access_license":null,"pmc_open_access_status":null,"unpaywall_open_access_pdf_url":null,"unpaywall_open_access_landing_url":null,"unpaywall_open_access_license":null,"unpaywall_open_access_status":null,"abstract":"Abstract Age-related macular degeneration (AMD), diabetic retinopathy and retinal vein occlusion represent some of the commonest degenerative conditions that lead to severe vision impairment in the developed countries. The gold standard treatment of complications associated with these conditions is the intravitreal administration of anti-vascular endothelial growth factor (VEGF) agents. Brolucizumab is a newly developed, humanised, single-chain fragment of a monoclonal antibody binding all VEGF-A isoforms, which was recently approved for the treatment of neovascular AMD. Intravitreal brolucizumab promises to reduce treatment burden for nAMD patients by achieving comparable therapeutic outcomes with fewer clinic visits. Promising also appears its use for the treatment of more challenging maculopathies like diabetic macular oedema (DMO). The aim of this review is to describe the special pharmacological properties of brolucizumab and display the outcomes of the most important clinical trials and real-world studies regarding its efficacy and safety for the management of degenerative macular disorders.","claims":[{"public_id":"cl_cb268e3ad958af1af645d8d73e0a0634","status":"active","text":"Brolucizumab appears promising for more challenging maculopathies such as diabetic macular oedema.","confidence":0.78,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_cb268e3ad958af1af645d8d73e0a0634"},{"public_id":"cl_1a162f6fe22aa501ad8498b8c2d4a225","status":"active","text":"Brolucizumab binds all VEGF-A isoforms and was recently approved for neovascular age-related macular degeneration.","confidence":0.98,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_1a162f6fe22aa501ad8498b8c2d4a225"},{"public_id":"cl_90d1fa0e7e6629275ebe6f2f2027e15f","status":"active","text":"Clinical trials and real-world studies on brolucizumab are reviewed for efficacy and safety in degenerative macular disorders.","confidence":0.96,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_90d1fa0e7e6629275ebe6f2f2027e15f"},{"public_id":"cl_7840e9894ac730c62b93d44a287e46d9","status":"active","text":"Intravitreal brolucizumab is expected to reduce treatment burden in neovascular age-related macular degeneration by achieving comparable therapeutic outcomes with fewer clinic visits.","confidence":0.9,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_7840e9894ac730c62b93d44a287e46d9"}],"concepts":[{"public_id":"co_019ee9ac763b9a9e8e46b02b2fd81c71","status":"active","name":"treatment burden","description":"The amount of clinical monitoring, injections, and visits required to manage a chronic eye disease.","types":["outcome","care burden"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_019ee9ac763b9a9e8e46b02b2fd81c71"},{"public_id":"co_06bded63865aa73bb7ef1ee72dba9118","status":"active","name":"VEGF-A isoforms","description":"The different molecular forms of vascular endothelial growth factor A targeted by brolucizumab.","types":["molecular target"],"aliases":["vascular endothelial growth factor A isoforms"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_06bded63865aa73bb7ef1ee72dba9118"},{"public_id":"co_0b8dd3a1cfe0a49ba3fa4d93a998cb11","status":"active","name":"clinical trials","description":"Controlled clinical studies evaluating the efficacy and safety of an intervention.","types":["study type"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_0b8dd3a1cfe0a49ba3fa4d93a998cb11"},{"public_id":"co_0e0b142aa73ed09b282db564e9505bca","status":"active","name":"diabetic macular oedema","description":"Macular swelling caused by diabetic retinal vascular disease.","types":["disease"],"aliases":["DMO"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_0e0b142aa73ed09b282db564e9505bca"},{"public_id":"co_3a921bd382d872430f8e2a84eca0d7e8","status":"active","name":"intravitreal brolucizumab","description":"Administration of brolucizumab directly into the eye's vitreous cavity.","types":["administration route","treatment"],"aliases":["intravitreal administration of brolucizumab"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_3a921bd382d872430f8e2a84eca0d7e8"},{"public_id":"co_543751d8ee82f3f36297e41741a1e257","status":"active","name":"intravitreal administration","description":"Delivery of a drug into the vitreous cavity of the eye.","types":["administration route"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_543751d8ee82f3f36297e41741a1e257"},{"public_id":"co_5d90f4e2c48783667968bd3385691b99","status":"active","name":"anti-vascular endothelial growth factor agents","description":"Drugs that inhibit VEGF signaling to treat neovascular retinal disease.","types":["drug class"],"aliases":["anti-VEGF agents","anti-VEGF"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_5d90f4e2c48783667968bd3385691b99"},{"public_id":"co_7214aea89ae8736cc8c60353bbca8b4b","status":"active","name":"neovascular age-related macular degeneration","description":"A form of age-related macular degeneration characterized by choroidal neovascularization and severe vision loss.","types":["disease"],"aliases":["nAMD"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_7214aea89ae8736cc8c60353bbca8b4b"},{"public_id":"co_865570baee5ef6608650da554fe5c363","status":"active","name":"real-world studies","description":"Observational studies reporting outcomes from routine clinical practice.","types":["study type"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_865570baee5ef6608650da554fe5c363"},{"public_id":"co_97afb39964f8ce4b4733dc01c6a6c039","status":"active","name":"degenerative macular disorders","description":"A group of retinal macular diseases associated with degeneration and vision impairment.","types":["disease category"],"aliases":["degenerative macular conditions"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_97afb39964f8ce4b4733dc01c6a6c039"},{"public_id":"co_f0cd768b2c5a15aef8dd6b7f178acb62","status":"active","name":"maculopathies","description":"Diseases affecting the macula, the central region of the retina responsible for detailed vision.","types":["disease category"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_f0cd768b2c5a15aef8dd6b7f178acb62"},{"public_id":"co_f9a425cd4e805f76e9e439e1d02ca988","status":"active","name":"brolucizumab","description":"A humanized single-chain antibody fragment that binds VEGF-A and is used by intravitreal injection for retinal disease.","types":["drug","therapeutic agent"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_f9a425cd4e805f76e9e439e1d02ca988"}],"external_ids":{"DOI":"10.2147/DDDT.S378450","ArXiv":null,"PubMed":35971530,"PubMedCentral":"9375562","MAG":null,"DBLP":null,"ACL":null},"open_access":{"is_open_access":true,"pdf_url":"https://www.dovepress.com/getfile.php?fileID=82865","landing_url":"https://www.semanticscholar.org/paper/529b13a6f3c8b3efc9b37991f2e808707bd8ac3e","source":"semantic_scholar","pdf_url_source":"semantic_scholar_open_access_pdf","license":"CCBYNC","status":"GOLD","reason":null},"reference_availability":{"status":"available","references_indexed":true,"full_text_available":false,"full_text_source":null,"count_basis":"semantic_scholar_metadata","extraction_status":"not_applicable","reason":null},"source":{"provider":"episteme2","base_corpus":"semantic_scholar_dump","freshness_mode":"unknown","basis":["semantic_scholar_metadata","postgres_metadata"],"limits":["paper metadata is based on indexed upstream scholarly datasets","claims and concepts are available only for extracted papers","absence of claims or concepts means no extracted graph data is available in this response"],"status":"available","degraded":false,"degraded_reasons":[],"diagnostics":{"status":"available","degraded":false,"degraded_reasons":[],"metadata_status":"available","graph_status":"available","abstract_status":"available"},"source_flags":5},"paper_id":634791,"paper_uid":"a70d6395-c0c2-4a49-bc9a-8103783d64ac","canonical_identity":{"paper_id":634791,"paper_uid":"a70d6395-c0c2-4a49-bc9a-8103783d64ac","identity_status":"available","lookup_basis":"semantic_scholar_external_id","compatibility_path":"corpus_id"},"url":"https://sah.borca.ai/papers/251478343"}